Clinical trial
An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate…
NCT00153010 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00153010 |
|---|---|
| Title | An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type |
| Official title | A Phase II Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled, Multicenter, Safety and Efficacy Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Alzheimer Disease |
| Intervention type | Drug |
| Interventions | NS 2330 (Tesofensine) |
| Enrollment | 430 |
| Start date | Feb 1, 2003 |
| Primary completion | Mar 1, 2005 |
| First posted | Sep 12, 2005 |
| Last update posted | Oct 29, 2013 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: